MyAverix Finance MyAverix Finance

F · Healthcare

CAPRICOR THERAP. DL-001 (4LN2)

Biotechnology

CAPRICOR THERAP. DL-001 (4LN2) is listed on F in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 4LN2

P/E ratio
25.00

CAPRICOR THERAP. DL-001 (4LN2) — FAQ

What is 4LN2's P/E ratio?

The price-to-earnings (P/E) ratio for CAPRICOR THERAP. DL-001 (4LN2) is 25.00 (data as of 2026-05-23).

Does CAPRICOR THERAP. DL-001 pay a dividend?

Dividend yield is not available in the current snapshot for CAPRICOR THERAP. DL-001 (4LN2). Check the MyAverix Finance app for the latest dividend data.

What sector is CAPRICOR THERAP. DL-001 in?

CAPRICOR THERAP. DL-001 (4LN2) is classified in the Healthcare sector (Biotechnology industry).

What exchange is 4LN2 listed on?

4LN2 is listed on F.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play